Related Experiment Videos
[Handling small relative risks in science and management: the third-generation pill]
J P Vandenbroucke1, K W Bloemenkamp, F M Helmerhorst
1Afd. Klinische Epidemiologie, Leids Universitair Medisch Centrum, Leiden.
Nederlands Tijdschrift Voor Geneeskunde
|February 25, 2000
Summary
Small increases in disease risk are scientifically accepted if findings are consistent, biases are addressed, and a biological mechanism exists. The third-generation oral contraceptive controversy highlights challenges in interpreting and applying these small risks in medical practice.
Area of Science:
- Epidemiology
- Medical Practice Guidelines
Background:
- Small relative risks (≤2-fold increase in disease) require rigorous scientific validation.
- Consistent findings, bias control, and plausible biologic mechanisms are key criteria for scientific acceptance.
Purpose of the Study:
- To examine the criteria for accepting small relative risks in scientific research.
- To use the third-generation oral contraceptive controversy as a case study.
Main Methods:
- Review of scientific criteria for risk assessment.
- Analysis of the third-generation oral contraceptive case study.
Main Results:
- Small relative risks are scientifically acceptable when supported by consistent evidence, robust bias/confounding control, and a plausible biologic mechanism.
- The third-generation oral contraceptive controversy exemplifies the difficulties in translating such findings into clinical practice.
Conclusions:
- Interpreting and implementing small relative risks into medical guidelines presents significant challenges.
- The case of third-generation oral contraceptives underscores the need for clear frameworks for managing evidence of small effect sizes.